Yahoo Finance

AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new efficacy and safety data from the first ...
Business Wire

AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular ...

Advancement of the study into the Phase 2 expansion follows the successful completion of the Phase 1 dose escalation portion of the trial, where 1.0 mg of tivozanib was administered for 21 days ...
Pharmabiz

AVEO Oncology announces positive results from phase portion of DEDUCTIVE trial of Fotivda in combo with Imfinzi to treat patients with advanced or metastatic HCC

AVEO Oncology (formerly known as AVEO Pharmaceuticals) announced the presentation of results from the phase 1b portion of the phase 1b/2 DEDUCTIVE clinical trial of tivozanib (Fotivda), AVEO’s ...
Nasdaq

AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular ...

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next ...